Verdiva Bio Advances Obesity Therapy with Once-Weekly Oral GLP-1 Peptide Analog
Is the pharmaceutical industry on the brink of a breakthrough in obesity treatment? Verdiva Bio Limited a clinical-stage biopharmaceutical company focused on developing innovative therapies for obesity and cardiometabolic disorders, has announced the completion of enrollment for its Phase 2b EVOLVE-2 clinical study of VRB-101. This once-weekly oral, cAMP-biased, GLP-1 peptide analog candidate is designed for body weight reduction in people with overweight or obesity. The company expects to report topline data from the study by the end of 2026.
Key Insights at a Glance
- Study Completion: Verdiva Bio has completed enrollment for its Phase 2b EVOLVE-2 study, enrolling over 200 participants.
- Primary Endpoint: The primary endpoint is mean percentage body weight change from baseline.
- Future Trials: Assuming positive results, Verdiva Bio plans to initiate Phase 3 clinical trials for VRB-101 during 2027.
- Drug Potential: VRB-101 has the potential to become a first-in-class once-weekly oral GLP-1 analog.
The Multifaceted Challenge of Obesity
Obesity is a multifactorial chronic disease with significant health-related complications, necessitating long-term therapy. Current treatments often involve injectable GLP-1 peptides, which can be inconvenient and less patient-friendly. Verdiva Bio’s VRB-101 aims to address this gap by offering a once-weekly oral alternative. The EVOLVE-2 study, a randomized, double-blind, placebo-controlled Phase 2b trial, is designed to evaluate the safety, tolerability, and efficacy of VRB-101 for body weight reduction. With over 200 participants enrolled, the study is a critical step in advancing the treatment landscape for obesity and related comorbidities.
The Clock Is Ticking on Obesity Treatment
Just as a ticking clock marks the urgency of time, Verdiva Bio is racing against the clock to bring a more convenient and effective obesity treatment to market. The EVOLVE-2 study is a pivotal moment, with the company aiming to report topline data by the end of 2026. Positive results could pave the way for Phase 3 trials, scheduled to begin in 2027. The potential of VRB-101 to become a first-in-class once-weekly oral GLP-1 analog underscores the company’s commitment to transforming the lives of millions living with obesity.
Verdiva Bio Mobilizes for Clinical Advancement
Verdiva Bio Limited is committed to developing next-generation therapies to help people living with obesity, cardiometabolic disorders, and related complications achieve better outcomes via patient-friendly therapeutic options. The EVOLVE-2 study, which has completed enrollment, is a significant milestone in the company’s clinical development program. Dr. Mohamed Eid, CMO at Verdiva Bio, stated, “Previous studies indicate a promising clinical profile for VRB-101, supported by PK modelling which suggest VRB-101’s ability to achieve drug levels similar to or higher than a once-weekly injectable GLP-1 peptide currently approved in the US and other major markets.” The company is also investigating VRB-101 in combination with its potential once-weekly oral amylin analog, VRB-103, further expanding its therapeutic portfolio.
Future Outlook
The journey to a more effective obesity treatment is like a marathon, with each clinical trial marking a crucial milestone. Verdiva Bio’s completion of the EVOLVE-2 study is a significant step forward, with the company expecting to report topline data by the end of 2026. Assuming positive results, the initiation of Phase 3 clinical trials in 2027 will be the next critical phase in bringing VRB-101 to market.
Conclusion
The completion of the EVOLVE-2 study is a testament to Verdiva Bio’s dedication to advancing obesity treatment. By developing a once-weekly oral GLP-1 peptide analog, the company is addressing a significant unmet need in the pharmaceutical industry. This milestone underscores the potential of VRB-101 to transform the lives of millions living with obesity. Join the conversation in the comments below.
About Verdiva Bio
Verdiva Bio is committed to developing next-generation therapies to help people living with obesity, cardiometabolic disorders, and related complications achieve better outcomes via patient-friendly therapeutic options. Verdiva Bio’s most advanced investigational candidate is VRB-101, an oral GLP-1 peptide analog in clinical development that has exhibited best-in-class efficacy potential in a Phase 1 study in Australia, which also supports the potential for once-weekly dosing.
The Company is also developing a portfolio of amylin molecules, including oral and subcutaneous agonists, and other undisclosed programs that offer the potential for enhanced efficacy, improved tolerability, and healthier weight loss. The Verdiva Bio team is harnessing the emerging science in gut-brain biology and leveraging their history of successful drug development to advance novel therapeutic options aiming to transform the lives of millions living with obesity worldwide.
Source link: https://www.businesswire.com/
